By Sabela Ojea

AstraZeneca PLC said Monday that its Forxiga drug has been approved in the European Union for the treatment of chronic kidney disease in adults with or without type 2 diabates.

The British-Swedish drugmaker said the approval is based on positive results from the DAPA-CKD phase three trial.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

August 09, 2021 02:53 ET (06:53 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AstraZeneca Charts.